Springer series on chemical sensors and biosensors, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 266, P. 131379 - 131379
Published: April 4, 2024
Language: Английский
Citations
7
Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 165, P. 115023 - 115023
Published: June 16, 2023
Dual-receptor targeted (DRT) nanoparticles which contain two distinct targeting agents may exhibit higher cell selectivity, cellular uptake, and cytotoxicity toward cancer cells than single-ligand nanoparticle systems without additional functionality. The purpose of this study is to prepare DRT poly(lactic-co-glycolic acid) (PLGA) for the delivery docetaxel (DTX) EGFR PD-L1 receptor positive such as human glioblastoma multiform (U87-MG) non-small lung (A549) lines. Anti-EGFR anti-PD-L1 antibody were decorated on DTX loaded PLGA DRT-DTX-PLGA via. single emulsion solvent evaporation method. Physicochemical characterizations DRT-DTX-PLGA, particle size, zeta-potential, morphology, in vitro release also evaluated. average size was 124.2 ± 1.1 nm with spherical smooth morphology. In uptake study, endocytosed by U87-MG A549 ligand nanoparticle. From cytotoxicity, apoptosis studies, we reported that exhibited high enhanced apoptotic compared ligand-targeted dual mediated endocytosis showed a binding affinity effect leads intracellular concentration cytotoxic properties. Thus, have potential improve therapy providing selectivity over single-ligand-targeted nanoparticles.
Language: Английский
Citations
14
Biomedicines, Journal Year: 2024, Volume and Issue: 12(3), P. 500 - 500
Published: Feb. 23, 2024
Based on the unprecedented results observed in recent clinical trials, antibody-drug conjugates (ADCs) have revolutionized treatment algorithm of metastatic breast cancer (mBC). The strategy sequencing different ADCs other lines therapy is highly attractive, but proportion patients who undergone such a context published trials still limited, especially for modern ADCs. HER2-positive disease primarily managed with sequence Historically, trastuzumab emtansine (T-DM1) has been most commonly used ADC both early and disease. Considering evidence related to deruxtecan (T-DXd), it expected assume role main our practice. Herein, we report retrospective analysis relying available data from trials.
Language: Английский
Citations
6
The Journal of venomous animals and toxins including tropical diseases, Journal Year: 2023, Volume and Issue: 29
Published: Jan. 1, 2023
Snakebite envenoming is a significant global health challenge, and for over century, traditional plasma-derived antivenoms from hyperimmunized animals have been the primary treatment against this infliction. However, these several inherent limitations, including risk of causing adverse reactions when administered to patients, batch-to-batch variation, high production costs. To address issues improve outcomes, development new types crucial. During development, key aspects such as improved clinical efficacy, enhanced safety profiles, greater affordability should be in focus. achieve goals, modern biotechnological methods can applied discovery therapeutic agents that neutralize medically important toxins multiple snake species. This review highlights some agents, monoclonal antibodies, nanobodies, selected small molecules, broad toxin neutralization, favorable produced on large scale with standardized manufacturing processes. Considering strengths limitations related pharmacokinetics different combination them might beneficial antivenom products properties. While implementation therapies requires time, it foreseeable application advancements represents promising trajectory toward snakebite envenoming. As research continue advance, could emerge mainstay future.
Language: Английский
Citations
13
Plant Growth Regulation, Journal Year: 2023, Volume and Issue: 103(2), P. 227 - 241
Published: Dec. 10, 2023
Language: Английский
Citations
10
Animals, Journal Year: 2025, Volume and Issue: 15(4), P. 472 - 472
Published: Feb. 7, 2025
Monoclonal antibody therapy has been a cornerstone of human healthcare for nearly four decades, effectively treating wide range diseases including cancers, autoimmune disorders, and inflammatory conditions. However, its application in veterinary medicine is relatively recent development, offering promising therapeutic approach managing chronic small animals. Dogs cats, like humans, suffer from conditions such as cancer, arthritis, allergies, pain, which mAb could potentially address. This review aims to explore the potential animal medicine, focusing on currently authorized products, their mechanisms action, clinical efficacy, safety concerns. A comprehensive literature was conducted evaluate use mAbs specifically treatment disorders. While shown significant benefits healthcare, challenges remain practice, concerns limited availability approved products. Despite these challenges, holds great promise improving management animals, with future research development expanding use.
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 381, P. 113562 - 113562
Published: Feb. 22, 2025
Language: Английский
Citations
0
EJNMMI Research, Journal Year: 2025, Volume and Issue: 15(1)
Published: March 24, 2025
Monoclonal antibodies are highly specific for their targets making them effective cancer therapy. However, large molecular weight causes slow blood clearance, often requiring weeks to be removed from circulation. This limitation affects companion nuclear imaging and antibody-based diagnostics, necessitating delayed imaging. We report the expansion of a methodology improving positron emission tomography (PET) contrast lymphoma biomarker CD20 at early time points after radiolabeled antibody administration. Intact radioimmunoconjugates allowed stay in circulation long enough accumulate tumors, then, using chemical trigger, we induced rapid clearance radioactivity non-target tissues by cleaving linker between radioactivity. For brevity, refer this as Tetrazine KnockOut (TKO) method which uses transcyclooctene-tetrazine (TCO-Tz) reaction, wherein an is conjugated with containing TCO radioisotope. optimized several different radioisotopes evaluated ability tetrazines knockout circulating antibodies. explored cell types varying internalization rates, characterize parameters TKO tested [89Zr]Zr-DFO-TCO-rituximab model PET Tz or vehicle Treatment > 70% cleavage vitro within 30 min. Internalizing exhibited similar cellular uptake compared vehicle, whereas decreased was seen slowly internalizing In rodents, rapidly liberated antibody, cleared blood, accumulated bladder. resulted 50% organs following injection. No decrease tumor observed when rate higher model, target-to-background ratio increased twofold comparison nontreated groups 24 h. The approach potentiates rituximab has translational potential
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: April 28, 2025
The mpox disease, caused by the virus (MPXV), has become a rising public health issue due to its potential cause outbreaks. Consistently, this investigation aims evaluate current advances in development of novel immunotherapeutic approaches against MPXV, which are crucial for preventing and controlling spread. This scoping review was performed analyzing content English-language articles published between 2018 2024, reported next-generation vaccines MPXV their assessment animal models. Patents within scope research were also included. Contrarywise, studies based solely on immunoinformatic methods, reviews, book chapters, news, others excluded. literature search executed 11 databases, such as Scopus, MEDLINE, PubMed. A total 36 records (32 4 patents) included review. All 32 contain preclinical with varied group sizes (4-16) main models BALB/c mice. Less commonly used CAST/Ei mice cynomolgus macaques. Moreover, most targeted one or more antigens, A29L, A35R, B6R, M1R, through active immunization (via mRNAs recombinant antigens) passive (antibody delivery). Overall, new generation might represent prospective candidates combat concern. Nonetheless, several analyzed possess drawbacks, including limited similarity humans, small sizes, brief follow-up durations. Consequently, additional is required ascertain long-term protection, efficacy, safety these approaches.
Language: Английский
Citations
0
Current Gene Therapy, Journal Year: 2024, Volume and Issue: 25(2), P. 92 - 112
Published: May 23, 2024
Lung cancer is a significant cause of cancer-related death worldwide. It can be broadly categorised into small-cell lung (SCLC) and Non-small cell (NSCLC). Surgical intervention, radiation therapy, the administration chemotherapeutic medications are among current treatment modalities. However, application chemotherapy may limited in more advanced stages metastasis due to potential for adverse effects lack selectivity. Although small-molecule anticancer treatments have demonstrated effectiveness, they still face several challenges. The challenges at hand this context comprise insufficient solubility water, bioavailability specific sites, effects, requirement epidermal growth factor receptor inhibitors that genetically tailored. Bio-macromolecular drugs, including small interfering RNA (siRNA) messenger (mRNA), susceptible degradation when exposed bodily fluids humans, which reduce stability concentration. In context, nanoscale delivery technologies utilised. These agents offer encouraging prospects preservation regulation pharmaceutical substances, addition improving medications. Nanocarrier-based systems possess notable advantage facilitating accurate sustained drug release, as opposed traditional systemic methodologies. primary focus scientific investigation has been augment therapeutic efficacy nanoparticles composed lipids. Numerous techniques implemented treat various respiratory ailments, such cancer. exhibited mitigate limitations associated with conventional therapy. As an illustration, applying nanocarriers enhance drugs prevent bio-macromolecular drugs. Furthermore, these devices administer controlled extended fashion, thereby augmenting intervention's effectiveness reducing reactions. despite promising results, remain must addressed. Multiple factors necessitate consideration contemplating medical interventions. To begin with, advancement efficient methods imperative. addition, comprehensive toxicity required. Finally, additional research needed comprehend treatments' enduring ramifications. Despite challenges, field nanomedicine demonstrates considerable promise enhancing therapy other diseases.
Language: Английский
Citations
3